Groups
|
Rejection rate
|
P value
|
Non-relapse mortality (NRM)
|
P value
|
---|
10 years
|
10 years
|
---|
Mesenchymal group
|
Yes
|
14.46% (7.89–22.93%)
|
0.88
|
22.02% (13.69–31.59%)
|
0.222
|
No
|
15.52% (9.87–22.34%)
|
31.88% (22.66–41.47%)
|
Sex-matched
|
Mismatched
|
18.52% (11.66–26.61%)
|
0.08
|
31.20% (20.90–42.01%)
|
0.756
|
Matched
|
10.23% (5.21–17.23%)
|
26.74% (18.35–35.85%)
|
ABO-mismatched
|
Mismatched
|
18.32% (10.78–27.43%)
|
0.236
|
30.13% (20.32–40.53%)
|
0.543
|
Matched
|
12.53% (7.48–18.94%)
|
27.48% (18.50–37.21%)
|
Source of HSCT
|
PB
|
13.68% (8.45–20.17%)
|
0.404
|
32.12% (23.46–41.09%)
|
0.109
|
BM
|
17.39% (10.01–26.46%)
|
20.68% (12.32–30.55%)
|
Acute GvHD
|
Yes
|
15.95% (12.42–21.77%)
|
0.452
|
37.47% (28.06–46.85%)
|
0.256
|
No
|
22.86% (15.73–30.80%)
|
29.31% (21.10–39.21%)
|
Chronic GvHD
|
Yes
|
16.82% (12.46–25.31%)
|
0.249
|
26.77% (16.58–38.02%)
|
0.349
|
No
|
24.32% (17.44–31.83%)
|
27.70% (20.27–35.60%)
|
- TRM transplant-related mortality, GvHD graft-versus-host disease, BM bone marrow, PB peripheral blood